Seattle Genetics, Inc. Data Could Make 2010 A Banner Year; Regulatory Filings for Leukemia, Lymphoma Drugs Could Come First Half 2011

LOS ANGELES, Aug 19 (Reuters) - Seattle Genetics (SGEN.O), a developer of antibody-based drugs, could have important data as soon as this month from a trial of its experimental leukemia treatment, followed within weeks by results from two trials of another drug for lymphoma.

Back to news